Simone Cesaro
Simone Cesaro is an expert in Hematology at Azienda Ospedaliera Universitaria Integrata Verona (Italy). As of October 2026, ScienceLeadR ranks Simone Cesaro in the top 1% of experts worldwide for Bone Marrow Transplantation, Stem Cell Transplantation and Cell Transplantation. Simone Cesaro has authored 541 publications, the most recent in 2026, and is an investigator in 24 clinical trials, 5 of them ongoing. SLR score: 1,880 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Transplantation - Pediatrics - Infectiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Simone Cesaro, M.D., Pediatrician
Simone Cesaro is a distinguished Italian pediatrician and pediatric oncologist. Born in 1962, he graduated in Medicine and Surgery from the University of Padua in 1988. He completed his specialization in Pediatrics in 1992, also at the University of Padua. Since then, he has dedicated his career to pediatrics, with a particular focus on pediatric hematology-oncology.
In 1994, Cesaro became a clinical assistant at the Department of Pediatrics at the University of Padua, where he started working on pediatric hematopoietic stem cell transplantation (HSCT). In 1996, he spent six months as a visiting physician at the Bristol Royal Hospital for Sick Children in England.
In 2009, Cesaro was appointed Director of the the Pediatric Oncohematology at the University Hospital of Verona, where he continues to work today. Over his career, he has published more than 400 articles in peer-reviewed journals, focusing on bacterial and fungal infections, viral complications after HSCT, management of central venous catheters (CVC), post-transfusion hepatitis, the use of growth factors, HSCT for pediatric leukemias, and many other areas. He is also active in various scientific organizations, including the European Society for Blood and Marrow Transplantation (EBMT), the European Conference on Infections in Leukemia (ECIL), and the Italian Association of Pediatric Hematology and Oncology (AIEOP). He has held various leadership roles, such as President of the AIEOP Support and Infections Group and Chairman of the EBMT Infectious Diseases Working Party.
His dedication and contributions to research and clinical practice have had a significant impact on the field of pediatric hematology-oncology.
Organizations
Career arc: 1991 - 2026
Number : 541
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Malignancies in inborn errors of immunity: a retrospective-prospective study on a large Italian cohort of pediatric and adult patients. PMID 42851687 — registries, incidence, hematologic neoplasms, neoplasms, immune system diseases, prevalence, immunity, diagnosis, prospective studies | Front Immunol | 2026 | 0 |
| Cumulative Hematologic Morbidity and Outcomes in Shwachman-Diamond Syndrome. PMID 42777247 — shwachman-diamond syndrome, morbidity | N Engl J Med Top journal | 2026 | 0 |
| A survey on the institutional practices of the use of isavuconazole in onco-hematological children, on behalf of the Infectious Working Group of AIEOP. PMID 42773305 — hematology, safety, pharmaceutical preparations, drug monitoring, aged, mycoses, institutional practice, therapeutics, pediatrics, invasive fungal infections, infections, salvage therapy, child | Eur J Pediatr | 2026 | 0 |
| Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. PMID 42748428 — cells, precursor cell lymphoblastic leukemia-lymphoma, disease-free survival, leukemia, drug therapy, therapeutics, random allocation, b-lymphocytes, child, chemotherapy | N Engl J Med Top journal | 2026 | 2 |
| Invasive mold infection in pediatric acute lymphoblastic leukemia-a detailed analysis of the clinical trial AIEOP-BFM ALL2009. PMID 42527667 — precursor cell lymphoblastic leukemia-lymphoma, leukemia, infections | Leukemia | 2026 | 0 |
Clinical Studies 24
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| HR NBL2 High risk neuroblastoma study 2 0 of SIOP Europe Neuroblastoma SIOPEN Randomised international and multicentric phase 3 study that evaluates 3 therapeutic phases (induction high dose chemotherapy and radiotherapy) for patients with high risk neuroblastoma and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy 2024-514917-36-00 — radiotherapy, induction chemotherapy, drug therapy, therapeutics, neuroblastoma, chemotherapy | Phase 3 | Recruiting | 2024 |
| SIOP HRMB An international prospective trial on clinically high risk medulloblastoma (HR MB) in patients older than 3 years 2024-510578-25-00 — radiotherapy, medulloblastoma, therapeutics | Phase 3 | Recruiting | 2021 |
| Phase III Clinical Trial for CPX 351 in Myeloid Leukemia in Children with Down Syndrome 2018 2022-501457-37-00 — down syndrome, leukemia, leukemia, myeloid, child | Phase 3 | Recruiting | 2021 |
| Framework for Optimizing Refining and Unifying Management of HSCT in Pediatric ALL 2025-522052-13-00 — adrenal cortex hormones, therapeutics, conditioning, psychological, child | Phase 2/Phase 3 | Recruiting | 2025 |
| Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL class Philadelphia Chromosome Like B cell Acute Lymphoblastic Leukemia 2025-520982-39-00 — pilot projects, cells, genes, pilots, precursor cell lymphoblastic leukemia-lymphoma, dasatinib, pharmaceutical preparations, genes, abl, leukemia, drug therapy, gene fusion, adolescent, protein-tyrosine kinases, consolidation chemotherapy, tyrosine, therapeutics, chromosomes, philadelphia chromosome, b-lymphocytes, child, chemotherapy | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map